Biocon Ltd Share Price Today - Biocon Ltd Stock Price Live NSE/BSE

Biocon Ltd

NSE: BIOCON BSE: 532523

₹380.95

(3.36%)

Sun, 22 Mar 2026, 00:16 am

MTF 5xInvest in Biocon Ltd with 5x Leverage Buy with MTF

Market Cap616.8B

PE Ratio78.85

Dividend0.13

Health Technology

Pharmaceuticals: Major

24.5K

Biocon Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
61740.38
Net Profit
1429.40
P/B
1.89
Sector P/E
31.86
P/E
40.43
EV/EBITDA
12.35
Debt/Equity (Industry)
0.29
Interest Cover (Industry)
4.37
ROCE (Industry)
9.08
RONW (Industry)
6.98
ROE
6.90
ROCE
6.86
Debt/Equity
0.84
EPS (TTM)
5.05
Dividend Yield
0.10
Book Value
233.84
Interest Cover
3.10

Analysis

all

Pros

Cash flow for Biocon is expected to increase by more than 50% in 2 years time.
Biocon's earnings are expected to grow significantly at over 20% yearly.
Biocon's earnings growth is expected to exceed the India market average.
Biocon's earnings growth is expected to exceed the low risk savings rate of 7.2%.
Biocon's earnings are expected to exceed the low risk growth rate next year.

Cons

Biocon is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of Biocon's dividends as it is not paying a notable one for India.
No need to calculate the sustainability of Biocon's dividends in 3 years as they are not expected to pay a notable one for India.
Biocon is not paying a notable dividend for India, therefore no need to check if the payments are stable.
Biocon's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	54.45	54.45	54.45	60.64	60.64
FII	7.39	6.61	6.04	5.66	5.66
DII	21.71	22.10	22.82	15.72	15.37
Public	16.45	16.83	16.68	17.97	18.34
Government	0	0	0	0	0

Technical Analysis

RSI

48.69

MACD

-0.52

50 DMA

378.30

200 DMA

373.69

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	464.80	424.30	407.05	383.80	366.55	343.30	302.80
Fibonacci	424.30	408.83	399.27	383.80	368.33	358.77	343.30
Camarilla	400.94	397.23	393.51	383.80	386.09	382.38	378.66

Pivots Level: Classic

+81

464.80

+40.50

424.30

+23.25

407.05

383.80

Pivot Point

LTP: 380.95

-17.25

366.55

-40.50

343.30

-81

302.80

Moving Average

SMAEMA

Period

Value

10-EMA
381.65
20-EMA
382.92
30-EMA
382.62
50-EMA
382.02
100-EMA
379.71
200-EMA
372.53

Announcement Date	Purpose	Action	Ex Date
12 Feb 2026	board-meetings	Quarterly Results
06 Dec 2025	egm
11 Nov 2025	board-meetings	Quarterly Results
04 Jun 2025	dividend	Final Dividend - Rs. - 0.5	04 Jul 2025
08 May 2025	agm
08 May 2025	dividend	₹0.50 Dividend /Share	04 Jul 2025
05 Jun 2024	dividend	Final Dividend - Rs. - 0.5	05 Jul 2024
16 May 2024	agm
16 May 2024	dividend	₹0.50 Dividend /Share	05 Jul 2024
07 Jun 2023	dividend	Final Dividend - Rs. - 1.5	07 Jul 2023

Biocon Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Divis Laboratories Ltd

Biocon Ltd About

Biocon is engaged in the manufacture of biotechnology products and research services.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1978

Headquarters

CEO

Kiran Mazumdar Shaw

Employees

Contact

Website

http://www.biocon.com

co.secretary@biocon.com

Phone

91-80-28082808

Location

20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100

Year	History
2021	Biocon launches Everolimus tablets in US. Biocon enters out-licensing deal with Tabuk Pharmaceuticals. Biocon Biologics’ interchangeable biosimilar Insulin Glargine preferred on Express Scripts’ US formulary. Biocon enters Dow Jones Sustainability Emerging Markets Index. Biocon partners with Tabuk Pharmaceuticals for speciality generics in Middle East.
2022	Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India. Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business. Biocon enters commercialization agreement with Zentiva in Europe. Biocon ranks No. 8 in ‘Global Top Employers’ List by Science Magazine. Biocon Foundation receives ‘Mahatma Award 2022 for Excellence in Social Good. Biocon Sdn. Bhd. enters Malaysia Book of Records as largest integrated insulin facility.
2023	Biocon partners with Sandoz for Adalimumab BS distribution in Japan. Biocon recognized as Asia IP Elite 2023; IPR Team named Team of the Year. Biocon completes integration of Viatris’ Biosimilar Business in 31 European countries. Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada. Biocon acquires manufacturing facility of Eywa Pharma Inc. Biocon Biologics takes over commercialization of biosimilars from Viatris in 70+ emerging markets.
2024	Biocon ranked among Science Magazine’s Top 10 Global Employers. Biocon Foundation honored with ‘Doing Good for Bharat Awards 2024’ in Healthcare Category for ‘eLAJ Smart Clinics’. Biocon partners with Tabuk Pharmaceuticals to commercialize GLP-1 products in Middle East. Biocon Foundation and IISc organize OCTF Conference on AI in Oral Cancer. Biocon signs semi-exclusive distribution deal for generic Saxenda (Liraglutide) in Mexico.
2025	Biocon Biologics wins 'Data Privacy Program of the Year' at BW Tech World’s Tech Excellence Awards. Biocon Biologics wins two awards at Asia Pacific Biopharma Excellence Awards (ABEA). Biocon honored with Champion of CSR Award at ESG Impact Summit 2024.

Client Name	Order Side	QTY	Avg Price	Date
AHAN - I LTD	Sell	18928363	200.74	17 Mar 2023
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Buy	8061599	229.26	28 Feb 2023
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Buy	11749167	354.76	29 May 2020
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Sell	6528193	354.22	29 May 2020
MK FAMILY PRIVATE TRUST	Buy	1000000	1150	29 Mar 2017
SMK FAMILY PRIVATE TRUST	Buy	1000000	1150	29 Mar 2017
MURALI KRISHNAN KARAIKAL NARAYANASWAMY	Sell	2000000	1150	29 Mar 2017

Biocon Ltd News

Biocon Gets FDA Nod for Liraglutide Injection ANDA

Biocon Pharma Limited receives U.S. FDA approval for Liraglutide Injection ANDA, strengthening the company's complex drug portfolio following recent Saxenda approval.

12 Mar 2026

companies

Biocon Q3FY26 Revenue Rises 9.2% to ₹41,730 Million

Biocon Limited reported consolidated revenue of ₹41,730 million for Q3FY26, up 9.2% YoY. Net profit attributable to shareholders reached ₹1,438 million with EPS of ₹1.08.

12 Mar 2026

co actions results

FDA Eases Rules for Biosimilar Drug Makers

The FDA has reduced regulatory requirements for companies developing cheaper versions of expensive biologic drugs, potentially benefiting biosimilar manufacturers like Biocon.

09 Mar 2026

stocks

Biocon to Join JP Morgan India Credit Investor Trip

Biocon Limited announces participation in JP Morgan's annual flagship India Credit Investor Trip on March 11, 2026, via virtual group interaction format.

05 Mar 2026

stocks

Biocon Acquires OCRPS Worth ₹3,153 Crore in Subsidiaries

Biocon Limited acquired preference shares worth ₹3,153.44 crore in wholly owned subsidiaries Biocon Biosphere Limited and Biocon Pharma Limited for business and working capital requirements.

03 Mar 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800

Biocon Ltd

Biocon Share Price Live Chart

Summary

Analysis

Financials

Ratios

Shareholding

Technical Analysis

Corporate Actions

Peer Comparison

Biocon Ltd About

Contact

Biocon Ltd Company History

Deals

Biocon Ltd News